36 results about "Intrahepatic Cholangiocarcinoma" patented technology

The present application provides a prediction system for prognosis and survival of patients with intrahepatic cholangiocarcinoma, including: an acquisition module and a prediction module, and the acquisition module and the prediction module are connected in a wireless and / or wired manner. The prediction system can use the promoter methylation score as the only variable to predict the survival of patients with intrahepatic cholangiocarcinoma, and can also predict the survival of intrahepatic cholangiocarcinoma based on multiple variables including the promoter methylation score. The prognostic survival period of cancer patients has the advantages of high accuracy, strong reliability, and stable prediction.

The present invention provides a method for constructing a model for predicting the survival rate of patients with intrahepatic cholangiocarcinoma, comprising the following steps: 1) providing DNA methylation sequencing data of intrahepatic cholangiocarcinoma; 2) sequencing the DNA methylation Analyze the data and screen out several related promoter regions of intrahepatic cholangiocarcinoma; 3) use the several related promoter regions of intrahepatic cholangiocarcinoma to establish a model for predicting the survival rate of patients with intrahepatic cholangiocarcinoma . Through the prognostic markers of DNA methylation in patients with intrahepatic cholangiocarcinoma, the markers of DNA methylation are used as independent variables, and patients are divided into high mortality and low mortality risk groups. After experimental verification, this paper The invented model construction method can be used to predict the overall survival rate of patients with intrahepatic cholangiocarcinoma after surgery, and provide individualized adjuvant treatment strategies for patients with intrahepatic cholangiocarcinoma.

The invention relates to the technical field of medical bioengineering, and aims to provide an application of MMP7, CTSE or LAMC2 proteins in preparation of an intrahepatic cholangiocarcinoma diagnosis reagent. The application is used for preparing a reagent capable of identifying and diagnosing intrahepatic cholangiocarcinoma and distinguishing primary hepatocellular carcinoma by using at least one of the MMP7, the CTSE or the LAMC2 proteins, which means the identification and the distinguishing of the hepatocellular carcinoma and the intrahepatic cholangiocarcinoma are achieved by using thethree proteins independently or in a combined manner. According to the application of the MMP7, the CTSE or the LAMC2 proteins in preparation of the intrahepatic cholangiocarcinoma diagnosis reagent,the reagent or a kit product is prepared from the three proteins, the expression level of the proteins in blood is detected by an immunological related method and is used as a basis for diagnosing anintrahepatic cholangiocarcinoma marker. The application of the MMP7, the CTSE or the LAMC2 proteins in preparation of the intrahepatic cholangiocarcinoma diagnosis reagent can accurately and specifically judge the possibility of the intrahepatic cholangiocarcinoma, benign biliary diseases, the hepatocellular carcinoma and health status of a subject, and provides a basis of the next diagnosis and treatment scheme for doctors.